The anti-Chi3l1 antibodies can prevent hepatic platelet accumulation by neutralizing Chi3l1, which plays a critical role in exacerbating the liver injury, and can be the new drug targets for AILI and perhaps other acute liver injury conditions
Targeting Chi3l1 by monoclonal antibodies in solid tumors is a novel strategy and has the potential to become the first-in-class therapeutics for the treatment of many solid tumor types, including HCC and metastatic breast cancer
Targeting Chi3l1 produced by tumor-associated macrophages could be promising immunotherapy targeting the tumor microenvironment